As our data suggest that activation of NRF2 forms an important component of the G12Ci-induced anti-cancer effect, we would expect that tumours with genetic activation of NRF2, which would not benefit from G12Ci-mediated NRF2 activation, would have worse prognosis that tumours with a fully functioning NRF2 response. This evidence concerns the gene NFE2L2 and cancer.